Papalazarou, Vasileios http://orcid.org/0000-0003-3206-401X
Newman, Alice C.
Huerta-Uribe, Alejandro
Legrave, Nathalie M. http://orcid.org/0000-0003-1172-4955
Falcone, Mattia http://orcid.org/0000-0003-0906-5735
Zhang, Tong
McGarry, Lynn http://orcid.org/0000-0002-7055-2615
Athineos, Dimitris http://orcid.org/0000-0001-5298-7941
Shanks, Emma
Blyth, Karen http://orcid.org/0000-0002-9304-439X
Vousden, Karen H. http://orcid.org/0000-0002-7365-1766
Maddocks, Oliver D. K. http://orcid.org/0000-0002-5551-9091
Funding for this research was provided by:
Cancer Research UK (C53309/A19702, C53309/A19702, C53309/A19702, C53309/A19702, A17196, A17196, A29799, A17196, A17196, A29799, C53309/A19702, CC2073, CC2073)
European Molecular Biology Organization (276-2019)
Article History
Received: 19 September 2022
Accepted: 26 October 2023
First Online: 8 December 2023
Competing interests
: Cancer Research Technology owns a patent filing relating to SLC inhibition. O.D.K.M. is a co-founder, shareholder and board member of Faeth Therapeutics and contributed to the CRUK Cancer Research Technology filing of patent application WO/2017/144877. K.H.V. is on the board of directors and shareholder of Bristol Myers Squibb and on the science advisory board (with stock options) of PMV Pharma, RAZE Therapeutics, Volastra Pharmaceuticals and Kovina Therapeutics. She is on the scientific advisory board of Ludwig Cancer and is a co-founder and shareholder of Faeth Therapeutics. She has been in receipt of research funding from Astex Pharmaceuticals and AstraZeneca and contributed to the CRUK Cancer Research Technology filing of patent application WO/2017/144877. The other authors declare no competing interests.